Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
HER-2 mutation
Cancer:
Urothelial Cancer
Drug:
Gilotrif (afatinib)
(
EGFR inhibitor
,
HER2 inhibitor
,
HER4 inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
New
Source:
J Clin Oncol
Title:
Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations
Excerpt:
Importantly, molecular alterations of two specific genes—HER2 and ERBB3—were found to be significantly predictive of afatinib efficacy
DOI:
10.1200/JCO.2015.66.3047
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login